Sign In
Buy DMTK
$0.0940
+0 (+0%)
At Close: Oct 21, 2024
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against DermTech, Inc. (OTC: DMTKQ) on b
Why Is DermTech (DMTK) Stock Down 26% Today?
08:04am, Monday, 24'th Jun 2024
DermTech (NASDAQ: DMTK ) stock is falling on Monday as investors prepare for the molecular diagnostic company's shares to be delisted later this week. DermTech received a notice from the Listing Qua
Crude Oil Rises 1%; DermTech Shares Plummet
12:08pm, Tuesday, 18'th Jun 2024
U.S. stocks traded mostly higher midway through trading, with the Dow Jones index gaining around 0.1% on Tuesday.
DermTech Files for Voluntary Chapter 11 Protection
08:05am, Tuesday, 18'th Jun 2024
SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today filed for voluntary cha
DermTech Reports First-Quarter 2024 Financial Results
04:05pm, Tuesday, 14'th May 2024
SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its first-quar
DermTech to Explore Strategic Alternatives and Implement Restructuring Plan
04:15pm, Thursday, 18'th Apr 2024
SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that the spec
SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the presentat
DermTech, Inc. (DMTK) Q4 2023 Earnings Call Transcript
11:16pm, Thursday, 29'th Feb 2024
DermTech, Inc. (DMTK) Q4 2023 Earnings Call Transcript
DermTech, Inc. (DMTK) Reports Q4 Loss, Misses Revenue Estimates
06:26pm, Thursday, 29'th Feb 2024
DermTech, Inc. (DMTK) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.93 per share a year ago.
DermTech Reports Fourth-Quarter 2023 Financial Results
04:01pm, Thursday, 29'th Feb 2024
SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its fourth-qua
DermTech Announces Release Date for Fourth-quarter 2023 Financial Results
08:05am, Tuesday, 13'th Feb 2024
SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, will host a conference call a
DermTech Announces Additional Restructuring Actions to Focus on Revenue Growth and Streamline Operations
04:30pm, Wednesday, 31'st Jan 2024
SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced additional re
DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test (DMT) Across All Skin Types
08:05am, Thursday, 18'th Jan 2024
SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported positive topli
DermTech Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-on Assay
08:05am, Tuesday, 16'th Jan 2024
SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that it will
NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against DermTech, Inc. (NASDAQ: DMTK) on behalf
